|
Jan 9
|
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
|
|
Dec 7
|
Lexaria's Investigational New Drug Application Filing Update
|
|
Nov 30
|
LEXX: GLP-1s’ Sweet Opportunity
|
|
Nov 28
|
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
|
|
Sep 29
|
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
|
|
Jul 19
|
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
|
|
Apr 24
|
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
|